ASP 8062

Drug Profile

ASP 8062

Alternative Names: ASP8062

Latest Information Update: 02 Feb 2017

Price : $50

At a glance

  • Originator Astellas Pharma
  • Class
  • Mechanism of Action GABA B receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Fibromyalgia

Most Recent Events

  • 31 Jan 2017 Phase-II clinical trials in Fibromyalgia in USA (PO) (Astellas Pharma pipeline, January 2017)
  • 31 Oct 2015 Phase-I clinical trials in Fibromyalgia (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top